cadapersen

Cadapersen (RO7191863, RG6084) is a GalNAc-conjugated, locked nucleic acid (LNA) antisense oligonucleotide designed to target and induce the degradation of Programmed Death-Ligand 1 (PD-L1) mRNA. Developed by Hoffmann-La Roche (Roche), it was engineered to achieve a functional cure for chronic hepatitis B (CHB) by reducing the expression of the PD-L1 immune checkpoint in the liver. In CHB, the PD-1/PD-L1 pathway is often upregulated, contributing to the exhaustion of HBV-specific T-cells. By silencing PD-L1 at the mRNA level, cadapersen aims to restore the host's immune response against the virus. It was primarily evaluated in Phase 2 clinical trials, such as the PIRANGA platform study, often in combination with other agents like the siRNA xalnesiran. However, in late 2024, Roche announced the discontinuation of its mid-phase hepatitis B portfolio, which included cadapersen.

Other names

cadapersen sodiumPD-L1 LNAPD-L-1 LNAPD-L 1 LNARO-7191863RO7191863RO 7191863RG-6084RG6084RG 6084